Overview
- Lilly reported third‑quarter revenue of $24.4 billion and adjusted earnings of $7.48 per share, both above analyst expectations.
- The company raised its full‑year revenue guidance to $91 billion–$92 billion from a prior $85 billion–$87 billion range.
- Mounjaro and Zepbound were major drivers with $10.72 billion and $5.35 billion in sales respectively, and overall GLP‑1 volume rose about 53% while realized prices fell roughly 15%.
- Lilly trimmed its adjusted profit outlook to $35.00–$36.00 per share after recording $4.57 per‑share acquired research charges mainly related to the AtaiBeckley and Curevo deals.
- Foundayo brought in $184 million, underperforming estimates, and investors are watching international rollouts and retatrutide — which showed about 24% average weight loss in midstage trials — ahead of a planned regulatory submission next year.